Cargando…

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes

HYPOTHESIS: Endoclip can be used as fiducial marker in urology. OBJECTIVE: To assess the feasibility, cost effectiveness and reliability of endoclips as novel fiducial markers in precision radiotherapy, as part of a trimodality bladder-preserving treatment (TBPT) of muscle-invasive bladder carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahbaz, Muhammad, Ammar, Asif, Wang, Yuliang, Farhaj, Zeeshan, Qiao, Liang, Niu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Urologia 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712701/ https://www.ncbi.nlm.nih.gov/pubmed/32271508 http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0713

Ejemplares similares

Editorial Comment: Endoclips as novel fiducial markers in trimodality bladder preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2014)

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes
por: Garcia, Maurice M., et al.
Publicado: (2016)

Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients
por: Arafat, Waleed, et al.
Publicado: (2016)

Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
por: Polineni, Praneet, et al.
Publicado: (2021)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer
por: Miyata, Haruka, et al.
Publicado: (2020)

Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis
por: Su, Xiaozhe, et al.
Publicado: (2023)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer
por: Liveringhouse, Casey, et al.
Publicado: (2023)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017)

Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A SEER database analysis
por: Shangguan, Wentai, et al.
Publicado: (2022)

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy
por: Magliocco, Anthony M., et al.
Publicado: (2022)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
por: Lee, Cheng-Yen, et al.
Publicado: (2014)

Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle‐invasive bladder cancer
por: Krishnatry, Rahul, et al.
Publicado: (2023)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis
por: Kim, Yeon Joo, et al.
Publicado: (2017)

Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers
por: Nishioka, Kentaro, et al.
Publicado: (2017)

A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy
por: Greer, Matthew D., et al.
Publicado: (2021)

Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
por: Azzarouali, Sana, et al.
Publicado: (2023)

Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis
por: Qiu, Junlan, et al.
Publicado: (2022)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis
por: Zhou, Yi-Xin, et al.
Publicado: (2023)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2018)

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
por: Fukushima, Hiroshi, et al.
Publicado: (2022)

Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review
por: Bos, Manouk K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4ejlfchpgnn9ogd9utn8j9atac